{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:02:35Z","timestamp":1789902155354,"version":"4.0.1"},"reference-count":309,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008865","name":"Xiamen University","doi-asserted-by":"publisher","award":["KFJJ-202414"],"award-info":[{"award-number":["KFJJ-202414"]}],"id":[{"id":"10.13039\/501100008865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008865","name":"Xiamen University","doi-asserted-by":"publisher","award":["202410384009"],"award-info":[{"award-number":["202410384009"]}],"id":[{"id":"10.13039\/501100008865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82561160102"],"award-info":[{"award-number":["82561160102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471446"],"award-info":[{"award-number":["82471446"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.phrs.2026.108432","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:04:43Z","timestamp":1788537883000},"page":"108432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic targeting of tauopathies: From druggable biology to precision intervention"],"prefix":"10.1016","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1434-0462","authenticated-orcid":false,"given":"Chengjia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinruo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2832-6590","authenticated-orcid":false,"given":"Yingjun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.phrs.2026.108432_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315383","article-title":"Tau Isoforms: gaining insight into MAPT alternative splicing","volume":"23","author":"Corsi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2026.108432_bib2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","article-title":"Roles of tau protein in health and disease","volume":"133","author":"Guo","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"13","key":"10.1016\/j.phrs.2026.108432_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137307","article-title":"Tau as a biomarker of neurodegeneration","volume":"23","author":"Holper","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41580-024-00753-9","article-title":"Cellular and pathological functions of tau","volume":"25","author":"Parra Bravo","year":"2024","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108432_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cells11050840","article-title":"What's in a Gene? The Outstanding Diversity of MAPT","volume":"11","author":"Ruiz-Gabarre","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40478-017-0489-6","article-title":"Atypical, non-standard functions of the microtubule associated Tau protein","volume":"5","author":"Sotiropoulos","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib8","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41374-019-0197-x","article-title":"MAPT mutations, tauopathy, and mechanisms of neurodegeneration","volume":"99","author":"Strang","year":"2019","journal-title":"Lab. Invest."},{"key":"10.1016\/j.phrs.2026.108432_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fneur.2013.00083","article-title":"The importance of tau phosphorylation for neurodegenerative diseases","volume":"4","author":"Noble","year":"2013","journal-title":"Front. Neurol."},{"issue":"13","key":"10.1016\/j.phrs.2026.108432_bib10","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1002\/j.1460-2075.1990.tb07870.x","article-title":"Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization","volume":"9","author":"Goedert","year":"1990","journal-title":"Embo J."},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12264-013-1411-2","article-title":"Regulation of alternative splicing of tau exon 10","volume":"30","author":"Qian","year":"2014","journal-title":"Neurosci. Bull."},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib12","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1021\/bi0521543","article-title":"Global hairpin folding of tau in solution","volume":"45","author":"Jeganathan","year":"2006","journal-title":"Biochemistry"},{"issue":"40","key":"10.1016\/j.phrs.2026.108432_bib13","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1021\/bi800783d","article-title":"The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments","volume":"47","author":"Jeganathan","year":"2008","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s004010100435","article-title":"The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease","volume":"103","author":"Leroy","year":"2002","journal-title":"Acta Neuropathol."},{"issue":"6257","key":"10.1016\/j.phrs.2026.108432_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/343461a0","article-title":"Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons","volume":"343","author":"Caceres","year":"1990","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1083\/jcb.114.4.725","article-title":"Overexpression of tau in a nonneuronal cell induces long cellular processes","volume":"114","author":"Knops","year":"1991","journal-title":"J. Cell. Biol."},{"issue":"17","key":"10.1016\/j.phrs.2026.108432_bib17","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1523\/JNEUROSCI.4261-13.2014","article-title":"Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers","volume":"34","author":"Frandemiche","year":"2014","journal-title":"J. Neurosci."},{"issue":"18","key":"10.1016\/j.phrs.2026.108432_bib18","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1016\/j.febslet.2009.08.017","article-title":"Function of tau protein in adult newborn neurons","volume":"583","author":"Fuster-Matanzo","year":"2009","journal-title":"FEBS Lett."},{"issue":"12","key":"10.1016\/j.phrs.2026.108432_bib19","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/hipo.20712","article-title":"Essential role of tau phosphorylation in adult hippocampal neurogenesis","volume":"20","author":"Hong","year":"2010","journal-title":"Hippocampus"},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm.2613","article-title":"Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export","volume":"18","author":"Lei","year":"2012","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib21","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.neurobiolaging.2014.05.005","article-title":"Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion","volume":"35","author":"Ahmed","year":"2014","journal-title":"Neurobiol. Aging"},{"issue":"1633","key":"10.1016\/j.phrs.2026.108432_bib22","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0144","article-title":"Microtubule-associated protein tau is essential for long-term depression in the hippocampus","volume":"369","author":"Kimura","year":"2014","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib23","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1091\/mbc.02-03-0046","article-title":"Protein kinase MARK\/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity","volume":"13","author":"Biernat","year":"2002","journal-title":"Mol. Biol. Cell."},{"issue":"41","key":"10.1016\/j.phrs.2026.108432_bib24","doi-asserted-by":"crossref","first-page":"12994","DOI":"10.1523\/JNEUROSCI.3531-09.2009","article-title":"Activated actin-depolymerizing factor\/cofilin sequesters phosphorylated microtubule-associated protein during the assembly of alzheimer-like neuritic cytoskeletal striations","volume":"29","author":"Whiteman","year":"2009","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2026.108432_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib26","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.neuint.2010.12.023","article-title":"Post-translational modifications of tau protein: implications for Alzheimer's disease","volume":"58","author":"Martin","year":"2011","journal-title":"Neurochem. Int."},{"issue":"3","key":"10.1016\/j.phrs.2026.108432_bib27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1471-4159.1993.tb03603.x","article-title":"Phosphoprotein phosphatase activities in Alzheimer disease brain","volume":"61","author":"Gong","year":"1993","journal-title":"J. Neurochem."},{"issue":"12","key":"10.1016\/j.phrs.2026.108432_bib28","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1111\/j.1460-9568.2007.05955.x","article-title":"Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation","volume":"26","author":"Liu","year":"2007","journal-title":"Eur. J. Neurosci."},{"issue":"9","key":"10.1016\/j.phrs.2026.108432_bib29","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1093\/brain\/awaa223","article-title":"Phosphorylated tau interactome in the human Alzheimer's disease brain","volume":"143","author":"Drummond","year":"2020","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nsmb.2555","article-title":"The microtubule-associated tau protein has intrinsic acetyltransferase activity","volume":"20","author":"Cohen","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib31","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1038\/s41467-023-41672-1","article-title":"Acetylation discriminates disease-specific tau deposition","volume":"14","author":"Chakraborty","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2026.108432_bib32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0306-4522(02)00510-9","article-title":"Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5","volume":"115","author":"Liu","year":"2002","journal-title":"Neuroscience"},{"issue":"29","key":"10.1016\/j.phrs.2026.108432_bib33","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1073\/pnas.0400348101","article-title":"O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease","volume":"101","author":"Liu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.phrs.2026.108432_bib34","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1039\/C0MB00337A","article-title":"Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation","volume":"7","author":"Smet-Nocca","year":"2011","journal-title":"Mol. Biosyst."},{"issue":"8","key":"10.1016\/j.phrs.2026.108432_bib35","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.jmb.2014.01.004","article-title":"O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers","volume":"426","author":"Yuzwa","year":"2014","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00401-011-0898-8","article-title":"Selective tau tyrosine nitration in non-AD tauopathies","volume":"123","author":"Reyes","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib37","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/hmg\/ddv059","article-title":"NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease","volume":"24","author":"Corsetti","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib38","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/brain\/awac022","article-title":"Establishing gene regulatory networks from Parkinson's disease risk loci","volume":"145","author":"Farrow","year":"2022","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib39","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.febslet.2005.03.041","article-title":"Nitration and oligomerization of tau induced by peroxynitrite inhibit its microtubule-binding activity","volume":"579","author":"Zhang","year":"2005","journal-title":"FEBS Lett."},{"issue":"42","key":"10.1016\/j.phrs.2026.108432_bib40","doi-asserted-by":"crossref","first-page":"10636","DOI":"10.1523\/JNEUROSCI.2143-06.2006","article-title":"Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies","volume":"26","author":"Reynolds","year":"2006","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1042\/BJ20140372","article-title":"Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity","volume":"462","author":"Funk","year":"2014","journal-title":"Biochem. J."},{"issue":"46","key":"10.1016\/j.phrs.2026.108432_bib42","doi-asserted-by":"crossref","first-page":"16586","DOI":"10.1073\/pnas.1417548111","article-title":"SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination","volume":"111","author":"Luo","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108432_bib43","article-title":"Tau post-translational modifications: dynamic transformers of tau function, degradation, and aggregation","volume":"11","author":"Alquezar","year":"2020","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddh083","article-title":"CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation","volume":"13","author":"Petrucelli","year":"2004","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib45","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1074\/jbc.M305838200","article-title":"CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival","volume":"279","author":"Shimura","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0896-6273(03)00606-8","article-title":"The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg","volume":"40","author":"Ciechanover","year":"2003","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40478-019-0663-0","article-title":"SET SUMOylation promotes its cytoplasmic retention and induces tau pathology and cognitive impairments","volume":"7","author":"Qin","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.phrs.2026.108432_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2024.1437995","article-title":"SUMO2 rescues neuronal and glial cells from the toxicity of P301L Tau mutant","volume":"18","author":"Orsini","year":"2024","journal-title":"Front. Cell. Neurosci."},{"issue":"5825","key":"10.1016\/j.phrs.2026.108432_bib49","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","article-title":"Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model","volume":"316","author":"Roberson","year":"2007","journal-title":"Science"},{"issue":"374","key":"10.1016\/j.phrs.2026.108432_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib51","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.108432_bib52","unstructured":"I.Ionis Pharmaceuticals, 2026. Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer\u2019s disease, https:\/\/ir.ionis.com\/news-releases\/news-release-details\/ionis-partner-biogen-announces-topline-results-phase-2-celia (accessed 21 June 2026)."},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102503","article-title":"Correcting tau isoform ratios with a long-acting antisense oligonucleotide alleviates 4R-tauopathy phenotypes","volume":"36","author":"Iwata-Endo","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib54","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s11011-020-00591-6","article-title":"Recent advances in tau-directed immunotherapy against Alzheimer's disease: an overview of pre-clinical and clinical development","volume":"35","author":"Ng","year":"2020","journal-title":"Metab. Brain Dis."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14283\/jpad.2018.45","article-title":"AADvac1, an active immunotherapy for Alzheimer's disease and non Alzheimer tauopathies: an overview of preclinical and clinical development","volume":"6","author":"Novak","year":"2019","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2026.108432_bib57","unstructured":"Axon Neuroscience SE, 2019. 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (ADAMANT), https:\/\/clinicaltrials.gov\/study\/NCT02579252?viewType=Card&intr=AADvac1&term=Tauopathies&rank=6 (accessed 21 June 2026)."},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.phrs.2026.108432_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104923","article-title":"Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the \"ADAMANT\" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial","volume":"99","author":"Cullen","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2026.108432_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105940","article-title":"Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b\/2a, multicentre, double-blind, randomised, placebo-controlled study","volume":"120","author":"Sol","year":"2025","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.phrs.2026.108432_bib61","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","article-title":"TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease","volume":"3","author":"Shulman","year":"2023","journal-title":"Nat. Aging"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib62","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40035-024-00429-6","article-title":"Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies","volume":"13","author":"Zhang","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.phrs.2026.108432_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105120","article-title":"Characterization of tau binding by gosuranemab","volume":"146","author":"Sopko","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108432_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102192","article-title":"Passive immunotherapy for Alzheimer's disease","volume":"94","author":"Guo","year":"2024","journal-title":"Ageing Res. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib65","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","article-title":"Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo","volume":"80","author":"Yanamandra","year":"2013","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib66","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.108432_bib67","article-title":"Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody","volume":"5","author":"Luo","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108432_bib68","unstructured":"I. Genentech, 2022. A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease, https:\/\/clinicaltrials.gov\/study\/NCT03289143?viewType=Card&term=Tauopathies&intr=semorinemab&rank=2 (accessed 21 June 2026)."},{"key":"10.1016\/j.phrs.2026.108432_bib69","unstructured":"I. Genentech, 2024. A Study of Semorinemab in Patients With Moderate Alzheimer's Disease, https:\/\/clinicaltrials.gov\/study\/NCT03828747?viewType=Card&term=Tauopathies&intr=semorinemab&rank=1 (accessed 21 June 2026)."},{"key":"10.1016\/j.phrs.2026.108432_bib70","unstructured":"Biogen, 2020. Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease, https:\/\/clinicaltrials.gov\/study\/NCT03056729?viewType=Card&term=Tauopathies&intr=BIIB076&rank=1 (accessed 21 June 2026)."},{"key":"10.1016\/j.phrs.2026.108432_bib71","unstructured":"I. Pinteon Therapeutics, 2021. A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-Ascending-Dose Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Intravenous PNT001 in Healthy Volunteers, https:\/\/trial.medpath.com\/zh\/clinical-trial\/2c2d29f14e9f6043\/nct04096287-phase-1-trial-pnt001-safety (accessed 21 June 2026)."},{"key":"10.1016\/j.phrs.2026.108432_bib72","unstructured":"UCBCares, 2022. A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD), https:\/\/www.ucb.com\/innovation\/clinical-studies\/clinical-studies-index\/Bepranemab-UCB0107 (accessed 21 June 2026)."},{"key":"10.1016\/j.phrs.2026.108432_bib73","unstructured":"L. Janssen Research & Development, 2026. A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease (Autonomy), https:\/\/clinicaltrials.gov\/study\/NCT04619420 (accessed 21 June 2026)."},{"key":"10.1016\/j.phrs.2026.108432_bib74","unstructured":"Eisai Inc, 2025. A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease, https:\/\/clinicaltrials.gov\/study\/NCT04971733 (accessed 21 June 2026)."},{"key":"10.1016\/j.phrs.2026.108432_bib75","unstructured":"Washington University School of Medicine, 2026. Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) (DIAN-TU), https:\/\/clinicaltrials.gov\/study\/NCT05269394 (accessed 21 June 2026)."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11064-022-03722-w","article-title":"Scrutinizing the therapeutic potential of PROTACs in the management of Alzheimer's disease","volume":"48","author":"Bhatia","year":"2023","journal-title":"Neurochem. Res."},{"issue":"39","key":"10.1016\/j.phrs.2026.108432_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202313869","article-title":"Harnessing nanochaperone-mediated autophagy for selective clearance of pathogenic tau protein in Alzheimer's disease","volume":"36","author":"Xu","year":"2024","journal-title":"Adv. Mater."},{"issue":"38","key":"10.1016\/j.phrs.2026.108432_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ady5212","article-title":"Gangliosides modulate the secretion of extracellular vesicles and their misfolded protein cargo","volume":"11","author":"Monyror","year":"2025","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib79","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0896-6273(93)90279-Z","article-title":"Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding","volume":"11","author":"Biernat","year":"1993","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib80","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1073\/pnas.90.11.5066","article-title":"The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development","volume":"90","author":"Goedert","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108432_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2024.115049","article-title":"Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease","volume":"383","author":"Merino-Serrais","year":"2025","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.phrs.2026.108432_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpath.2025.05.020","article-title":"Updates on tau-related drug targets and potential disease-modifying therapies for Alzheimer's disease","author":"Djurovic-Topalovic","year":"2025","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib83","doi-asserted-by":"crossref","first-page":"7972","DOI":"10.1038\/s41467-024-52075-1","article-title":"Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP","volume":"15","author":"Nadel","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2026.108432_bib84","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0197-4580(95)00025-A","article-title":"Tau domains, phosphorylation, and interactions with microtubules","volume":"16","author":"Mandelkow","year":"1995","journal-title":"Neurobiol. Aging"},{"issue":"19","key":"10.1016\/j.phrs.2026.108432_bib85","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1021\/acschemneuro.2c00314","article-title":"On the tracks of the aggregation mechanism of the PHF6 peptide from Tau protein: molecular dynamics, energy, and interaction network investigations","volume":"13","author":"Fagnen","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2026.108432_bib86","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.conb.2021.03.003","article-title":"A current view on Tau protein phosphorylation in Alzheimer's disease","volume":"69","author":"Wegmann","year":"2021","journal-title":"Curr. Opin. Neurobiol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-93304-x","article-title":"Geometry based prediction of tau protein sites and motifs associated with misfolding and aggregation","volume":"15","author":"Sugiyama","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108432_bib88","article-title":"Defined tau phosphospecies differentially inhibit fast axonal transport through activation of two independent signaling pathways","volume":"13","author":"Morris","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2026.108432_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102639","article-title":"Targeting tau in Alzheimer's and beyond: insights into pathology and therapeutic strategies","volume":"104","author":"Singh","year":"2025","journal-title":"Ageing Res. Rev."},{"issue":"3","key":"10.1016\/j.phrs.2026.108432_bib90","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S1471-4914(01)02266-3","article-title":"Glycogen synthase kinase 3: an emerging therapeutic target","volume":"8","author":"Eldar-Finkelman","year":"2002","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib91","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2026.108432_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.570223","article-title":"Chronic sodium selenate treatment restores deficits in cognition and synaptic plasticity in a murine model of tauopathy","volume":"13","author":"Ahmed","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"31","key":"10.1016\/j.phrs.2026.108432_bib93","doi-asserted-by":"crossref","first-page":"13888","DOI":"10.1073\/pnas.1009038107","article-title":"Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models","volume":"107","author":"van Eersel","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib94","article-title":"A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia","volume":"8","author":"Vivash","year":"2022","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000223","article-title":"Sodium selenate as a disease-modifying treatment for mild-moderate Alzheimer's disease: an open-label extension study","volume":"3","author":"Vivash","year":"2021","journal-title":"BMJ Neurol. Open."},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040100","article-title":"A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia","volume":"10","author":"Vivash","year":"2020","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib97","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","article-title":"Acetylation of tau inhibits its degradation and contributes to tauopathy","volume":"67","author":"Min","year":"2010","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib98","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/hmg\/ddt402","article-title":"Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance","volume":"23","author":"Cook","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"10","key":"10.1016\/j.phrs.2026.108432_bib99","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/nm.3951","article-title":"Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits","volume":"21","author":"Min","year":"2015","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib100","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/mdc3.12940","article-title":"Open-label phase 1 futility studies of salsalate and young plasma in progressive supranuclear palsy","volume":"7","author":"VandeVrede","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"10","key":"10.1016\/j.phrs.2026.108432_bib101","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2967\/jnumed.122.265225","article-title":"Development of a PET tracer for OGA with improved kinetics in the living brain","volume":"64","author":"Cook","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.phrs.2026.108432_bib102","unstructured":"S.A. Ferrer Internacional, 2023. Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP), https:\/\/ferrer.com\/en\/We-acquire-worldwide-rights-to-ASN90-an-O-GlcNAcase-inhibitor-to-treat-Progressive-Supranuclear-Palsy (accessed 3 February 2026)."},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib103","article-title":"Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease","volume":"10","author":"Kielbasa","year":"2024","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib104","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1124\/jpet.120.266122","article-title":"MK-8719, a novel and selective O-GlcNAcase inhibitor that reduces the formation of pathological tau and ameliorates neurodegeneration in a mouse model of tauopathy","volume":"374","author":"Wang","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40478-022-01457-x","article-title":"Artificial intelligence-derived neurofibrillary tangle burden is associated with antemortem cognitive impairment","volume":"10","author":"Marx","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"issue":"10","key":"10.1016\/j.phrs.2026.108432_bib106","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.neurobiolaging.2008.09.012","article-title":"Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease","volume":"31","author":"Braskie","year":"2010","journal-title":"Neurobiol. Aging"},{"issue":"9","key":"10.1016\/j.phrs.2026.108432_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094969","article-title":"The enigma of tau protein aggregation: mechanistic insights and future challenges","volume":"25","author":"Zheng","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"41","key":"10.1016\/j.phrs.2026.108432_bib108","doi-asserted-by":"crossref","first-page":"10752","DOI":"10.1021\/acs.jpcb.5c04935","article-title":"Hexagonal boron nitride nanoparticles for inhibition of small fragment tau aggregation","volume":"129","author":"Paul","year":"2025","journal-title":"J. Phys. Chem. B"},{"issue":"15","key":"10.1016\/j.phrs.2026.108432_bib109","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1021\/acs.jpcb.6b07045","article-title":"Primary fibril nucleation of aggregation prone tau fragments PHF6 and PHF6","volume":"121","author":"Smit","year":"2017","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.phrs.2026.108432_bib110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fnagi.2019.00204","article-title":"Role of tau as a microtubule-associated protein: structural and functional aspects","volume":"11","author":"Barbier","year":"2019","journal-title":"Front. Aging Neurosci."},{"issue":"10","key":"10.1016\/j.phrs.2026.108432_bib111","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1073\/pnas.97.10.5129","article-title":"Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure","volume":"97","author":"von Bergen","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"13","key":"10.1016\/j.phrs.2026.108432_bib112","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1021\/acs.jpcb.5b00175","article-title":"Tau assembly: the dominant role of PHF6 (VQIVYK) in microtubule binding region repeat R3","volume":"119","author":"Ganguly","year":"2015","journal-title":"J. Phys. Chem. B"},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib113","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2026.108432_bib114","doi-asserted-by":"crossref","DOI":"10.1038\/srep44739","article-title":"Signature of an aggregation-prone conformation of tau","volume":"7","author":"Eschmann","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib115","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4103\/1673-5374.385853","article-title":"Tau truncation in the pathogenesis of Alzheimer's disease: a narrative review","volume":"19","author":"Chu","year":"2024","journal-title":"Neural Regen. Res."},{"issue":"7721","key":"10.1016\/j.phrs.2026.108432_bib116","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41586-018-0454-y","article-title":"Structures of filaments from Pick's disease reveal a novel tau protein fold","volume":"561","author":"Falcon","year":"2018","journal-title":"Nature"},{"issue":"7802","key":"10.1016\/j.phrs.2026.108432_bib117","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-020-2043-0","article-title":"Novel tau filament fold in corticobasal degeneration","volume":"580","author":"Zhang","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.phrs.2026.108432_bib118","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1073\/pnas.91.12.5562","article-title":"Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease","volume":"91","author":"Alonso","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"13","key":"10.1016\/j.phrs.2026.108432_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109291","article-title":"Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition","volume":"35","author":"Waters","year":"2021","journal-title":"Cell. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s42003-025-07499-w","article-title":"Brain-derived tau oligomer polymorphs: distinct aggregations, stability profiles, and biological activities","volume":"8","author":"Lo Cascio","year":"2025","journal-title":"Commun. Biol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108432_bib121","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/alz.12321","article-title":"Visualization of neurofibrillary tangle maturity in Alzheimer's disease: a clinicopathologic perspective for biomarker research","volume":"17","author":"Moloney","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.phrs.2026.108432_bib122","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-pathmechdis-051222-120750","article-title":"Neurodegenerative disease tauopathies","volume":"19","author":"Creekmore","year":"2024","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib123","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13195-019-0511-2","article-title":"An experimental model of Braak's pretangle proposal for the origin of Alzheimer's disease: the role of locus coeruleus in early symptom development","volume":"11","author":"Ghosh","year":"2019","journal-title":"Alzheimers Res. Ther."},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib124","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","article-title":"Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years","volume":"70","author":"Braak","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib125","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1074\/jbc.M113.515445","article-title":"Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology","volume":"289","author":"Michel","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2026.108432_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030645","article-title":"Tau spreading mechanisms; implications for dysfunctional tauopathies","volume":"19","author":"Fuster-Matanzo","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108432_bib127","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/srep00700","article-title":"Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau","volume":"2","author":"Lasagna-Reeves","year":"2012","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.phrs.2026.108432_bib128","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00018-019-03349-1","article-title":"Mechanisms of secretion and spreading of pathological tau protein","volume":"77","author":"Brunello","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"issue":"44","key":"10.1016\/j.phrs.2026.108432_bib129","doi-asserted-by":"crossref","first-page":"14807","DOI":"10.1074\/jbc.RA120.014630","article-title":"Modulating disease-relevant tau oligomeric strains by small molecules","volume":"295","author":"Lo Cascio","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.phrs.2026.108432_bib130","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1016\/j.bpj.2025.06.009","article-title":"Intrinsic aggregation and propagation of unmodified tau peptides: R2R3 as a minimal model system","volume":"124","author":"Das","year":"2025","journal-title":"Biophys. J."},{"key":"10.1016\/j.phrs.2026.108432_bib131","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biochi.2022.05.013","article-title":"Tau R2 and R3 are essential regions for tau aggregation, seeding and propagation","volume":"200","author":"Annadurai","year":"2022","journal-title":"Biochimie"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib132","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40478-025-01930-3","article-title":"Tau oligomers impair memory and synaptic plasticity through the cellular prion protein","volume":"13","author":"Balducci","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"issue":"14","key":"10.1016\/j.phrs.2026.108432_bib133","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1016\/j.cell.2025.04.006","article-title":"Alzheimer's disease patient-derived high-molecular-weight tau impairs bursting in hippocampal neurons","volume":"188","author":"Harris","year":"2025","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib134","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40035-025-00479-4","article-title":"Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer's disease: a comprehensive review of the characteristics and therapeutic strategies","volume":"14","author":"Nam","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.phrs.2026.108432_bib135","unstructured":"TauRx Therapeutics Management Limited, 2024. MHRA confirms acceptance of UK Marketing Authorisation Application for HMTM, https:\/\/taurx.com\/news\/industry-news\/mhra-confirms-acceptance-of-uk-marketing-authorisation-application-for-hmtm (accessed 3 February 2026)."},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/nu14020248","article-title":"Post-ischemic brain neurodegeneration in the form of Alzheimer's disease proteinopathy: possible therapeutic role of curcumin","volume":"14","author":"Pluta","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.phrs.2026.108432_bib137","article-title":"Top-down engineered micron-cell derived nanovesicles encapsulating curcumin targeting the 3R strategy (remove, remodel, repair) for Alzheimer's disease therapy","volume":"34","author":"Chu","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"30","key":"10.1016\/j.phrs.2026.108432_bib138","doi-asserted-by":"crossref","first-page":"10227","DOI":"10.1021\/bi050387o","article-title":"Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases","volume":"44","author":"Necula","year":"2005","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001080","article-title":"Towards a pharmacophore for amyloid","volume":"9","author":"Landau","year":"2011","journal-title":"PLoS. Biol."},{"key":"10.1016\/j.phrs.2026.108432_bib140","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.46924","article-title":"Structure-based inhibitors of amyloid beta core suggest a common interface with tau","volume":"8","author":"Griner","year":"2019","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.phrs.2026.108432_bib141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0286523","article-title":"Small molecule inhibitor of tau self-association in a mouse model of tauopathy: a preventive study in P301L tau JNPL3 mice","volume":"18","author":"Davidowitz","year":"2023","journal-title":"PLoS. One"},{"issue":"3","key":"10.1016\/j.phrs.2026.108432_bib142","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70025","article-title":"Therapeutic treatment with OLX-07010 inhibited tau aggregation and ameliorated motor deficits in an aged mouse model of tauopathy","volume":"169","author":"Davidowitz","year":"2025","journal-title":"J. Neurochem."},{"issue":"18","key":"10.1016\/j.phrs.2026.108432_bib143","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202402007","article-title":"Functional selection of tau oligomerization-inhibiting aptamers","volume":"63","author":"Wang","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"3","key":"10.1016\/j.phrs.2026.108432_bib144","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1021\/acscentsci.3c01196","article-title":"Molecular deformation is a key factor in screening aggregation inhibitor for intrinsically disordered protein tau","volume":"10","author":"Chai","year":"2024","journal-title":"ACS Cent. Sci."},{"issue":"8","key":"10.1016\/j.phrs.2026.108432_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2025.167995","article-title":"Characterization of conformation-specific antibodies TOMA-1 and TTCM-1 for recombinant tau monomer and amplified brain derived tau oligomer","volume":"1871","author":"Haque","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"22","key":"10.1016\/j.phrs.2026.108432_bib146","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202401704R","article-title":"High-molecular-weight oligomer tau (HMWoTau) species are dramatically increased in Braak-stage dependent manner in the frontal lobe of human brains, demonstrated by a novel oligomer Tau ELISA with a mouse monoclonal antibody (APNmAb005)","volume":"38","author":"Fukumoto","year":"2024","journal-title":"Faseb J."},{"issue":"23","key":"10.1016\/j.phrs.2026.108432_bib147","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1039\/D4BM00707G","article-title":"Generation of nanobodies with conformational specificity for tau oligomers that recognize tau aggregates from human Alzheimer's disease samples","volume":"12","author":"McArthur","year":"2024","journal-title":"Biomater. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2026.108432_bib148","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3463","article-title":"Development of a pan-tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates","volume":"40","author":"McArthur","year":"2024","journal-title":"Biotechnol. Prog."},{"issue":"41","key":"10.1016\/j.phrs.2026.108432_bib149","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300258120","article-title":"Structure-based design of nanobodies that inhibit seeding of Alzheimer's patient-extracted tau fibrils","volume":"120","author":"Abskharon","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib150","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41541-024-00904-1","article-title":"Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers","volume":"9","author":"Tan","year":"2024","journal-title":"NPJ Vaccin."},{"issue":"15","key":"10.1016\/j.phrs.2026.108432_bib151","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2320456121","article-title":"Precision proteoform design for 4R tau isoform selective templated aggregation","volume":"121","author":"Longhini","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib152","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12035-025-05280-y","article-title":"Tau liquid\u2013liquid phase separation in Alzheimer\u2019s disease: mechanisms, pathogenesis, and therapeutic implications","volume":"63","author":"Tian","year":"2025","journal-title":"Mol. Neurobiol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib153","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201798049","article-title":"Tau protein liquid-liquid phase separation can initiate tau aggregation","volume":"37","author":"Wegmann","year":"2018","journal-title":"Embo J."},{"issue":"10","key":"10.1016\/j.phrs.2026.108432_bib154","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.celrep.2017.08.042","article-title":"Local nucleation of microtubule bundles through tubulin concentration into a condensed tau phase","volume":"20","author":"Hern\u00e1ndez-Vega","year":"2017","journal-title":"Cell. Rep."},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2002183","article-title":"RNA stores tau reversibly in complex coacervates","volume":"15","author":"Zhang","year":"2017","journal-title":"PLoS. Biol."},{"key":"10.1016\/j.phrs.2026.108432_bib156","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.42571","article-title":"Narrow equilibrium window for complex coacervation of tau and RNA under cellular conditions","volume":"8","author":"Lin","year":"2019","journal-title":"Elife"},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib157","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/pro.4101","article-title":"Liquid-liquid phase separation of Tau by self and complex coacervation","volume":"30","author":"Najafi","year":"2021","journal-title":"Protein Sci."},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib158","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41583-019-0222-5","article-title":"Stress granules and neurodegeneration","volume":"20","author":"Wolozin","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2026.108432_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2022.105342","article-title":"Molecular interaction of stress granules with Tau and autophagy in Alzheimer's disease","volume":"157","author":"Yu","year":"2022","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.phrs.2026.108432_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100260","article-title":"1,6-Hexanediol, commonly used to dissolve liquid-liquid phase separated condensates, directly impairs kinase and phosphatase activities","volume":"296","author":"D\u00fcster","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101222","article-title":"Myricetin slows liquid-liquid phase separation of Tau and activates ATG5-dependent autophagy to suppress Tau toxicity","volume":"297","author":"Dai","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108432_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2026.151806","article-title":"Ferulic acid inhibits Tau-441 liquid-liquid phase separation to restore glycolytic metabolism","volume":"358","author":"Lin","year":"2026","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib163","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1038\/s41467-023-41241-6","article-title":"Methylene blue accelerates liquid-to-gel transition of tau condensates impacting tau function and pathology","volume":"14","author":"Huang","year":"2023","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.phrs.2026.108432_bib164","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1039\/D4MH00023D","article-title":"Polycatechols inhibit ferroptosis and modulate tau liquid\u2013liquid phase separation to mitigate Alzheimer's disease","volume":"11","author":"Moorthy","year":"2024","journal-title":"Mater. Horiz."},{"issue":"98","key":"10.1016\/j.phrs.2026.108432_bib165","doi-asserted-by":"crossref","first-page":"13275","DOI":"10.1039\/D1CC05266G","article-title":"Regulation of liquid-liquid phase separation with focus on post-translational modifications","volume":"57","author":"Luo","year":"2021","journal-title":"Chem. Commun. (Camb.)"},{"issue":"52","key":"10.1016\/j.phrs.2026.108432_bib166","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2414176121","article-title":"GSK3\u03b2 phosphorylation catalyzes the aggregation of tau into Alzheimer's disease-like filaments","volume":"121","author":"Chakraborty","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib167","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41467-019-10792-y","article-title":"Lysine\/RNA-interactions drive and regulate biomolecular condensation","volume":"10","author":"Ukmar-Godec","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2026.108432_bib168","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051360","article-title":"Acetylation disfavors tau phase separation","volume":"19","author":"Ferreon","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108432_bib169","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bcp.2019.04.028","article-title":"New insights of poly(ADP-ribosylation) in neurodegenerative diseases: a focus on protein phase separation and pathologic aggregation","volume":"167","author":"Liu","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"21","key":"10.1016\/j.phrs.2026.108432_bib170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215501","article-title":"The role of post-translational modifications in the phase transitions of intrinsically disordered proteins","volume":"20","author":"Owen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib171","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/excr.2001.5263","article-title":"Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism","volume":"268","author":"Davidovic","year":"2001","journal-title":"Exp. Cell. Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib172","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/pro.4025","article-title":"Interplay between tau and \u03b1-synuclein liquid-liquid phase separation","volume":"30","author":"Siegert","year":"2021","journal-title":"Protein Sci."},{"key":"10.1016\/j.phrs.2026.108432_bib173","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ijbiomac.2022.04.034","article-title":"Zinc enhances liquid-liquid phase separation of Tau protein and aggravates mitochondrial damages in cells","volume":"209","author":"Gao","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib174","article-title":"Alzheimer's A\u03b2 catalyzes Tau phase separation and aggregation via early nanocluster solubilization","volume":"17","author":"Sun","year":"2026","journal-title":"Nat. Commun."},{"issue":"27","key":"10.1016\/j.phrs.2026.108432_bib175","doi-asserted-by":"crossref","first-page":"23504","DOI":"10.1021\/jacs.5c01369","article-title":"Chaperone-mediated regulation of tau phase separation, fibrillation, and toxicity","volume":"147","author":"M\u00f6rman","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.phrs.2026.108432_bib176","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.neuron.2021.03.026","article-title":"Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components","volume":"109","author":"Lester","year":"2021","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib177","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.molcel.2020.03.021","article-title":"ZAK\u03b1 recognizes stalled ribosomes through partially redundant sensor domains","volume":"78","author":"Vind","year":"2020","journal-title":"Mol. Cell."},{"issue":"5660","key":"10.1016\/j.phrs.2026.108432_bib178","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.1093133","article-title":"Nanotubular highways for intercellular organelle transport","volume":"303","author":"Rustom","year":"2004","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib179","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s40478-016-0386-4","article-title":"Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies","volume":"4","author":"Tardivel","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"issue":"9","key":"10.1016\/j.phrs.2026.108432_bib180","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1083\/jcb.201701047","article-title":"The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications For neurodegenerative diseases","volume":"216","author":"Victoria","year":"2017","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.phrs.2026.108432_bib181","article-title":"Possible mechanisms of tau spread and toxicity in Alzheimer\u2019s disease","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib182","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100760","article-title":"Ectosomes: a new mechanism for non-exosomal secretion of tau protein","volume":"9","author":"Dujardin","year":"2014","journal-title":"PLoS. One"},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib183","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1074\/jbc.M111.277061","article-title":"Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease","volume":"287","author":"Saman","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108432_bib184","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13287-015-0232-9","article-title":"Acellular approaches for regenerative medicine: on the verge of clinical trials with extracellular membrane vesicles?","volume":"6","author":"Fuster-Matanzo","year":"2015","journal-title":"Stem Cell. Res. Ther."},{"key":"10.1016\/j.phrs.2026.108432_bib185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-3804-9_1","article-title":"ER to golgi-dependent protein secretion: the conventional pathway","volume":"1459","author":"Viotti","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"23","key":"10.1016\/j.phrs.2026.108432_bib186","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/cbic.201800288","article-title":"Transcellular spreading of tau in tauopathies","volume":"19","author":"Demaegd","year":"2018","journal-title":"ChemBioChem"},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib187","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.celrep.2018.04.056","article-title":"Unconventional secretion mediates the trans-cellular spreading of tau","volume":"23","author":"Katsinelos","year":"2018","journal-title":"Cell. Rep."},{"issue":"8","key":"10.1016\/j.phrs.2026.108432_bib188","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.celrep.2018.10.078","article-title":"Secretion of tau via an unconventional non-vesicular mechanism","volume":"25","author":"Merezhko","year":"2018","journal-title":"Cell. Rep."},{"issue":"5","key":"10.1016\/j.phrs.2026.108432_bib189","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/jnc.15144","article-title":"Knockin\u2019 on heaven\u2019s door: molecular mechanisms of neuronal tau uptake","volume":"156","author":"De La-Rocque","year":"2020","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib190","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.celrep.2016.09.063","article-title":"Loss of bin1 promotes the propagation of tau pathology","volume":"17","author":"Calafate","year":"2016","journal-title":"Cell. Rep."},{"key":"10.1016\/j.phrs.2026.108432_bib191","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1146\/annurev.biochem.78.081307.110540","article-title":"Mechanisms of endocytosis","volume":"78","author":"Doherty","year":"2009","journal-title":"Annu. Rev. Biochem."},{"issue":"13","key":"10.1016\/j.phrs.2026.108432_bib192","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1016\/j.celrep.2018.03.021","article-title":"Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways","volume":"22","author":"Evans","year":"2018","journal-title":"Cell. Rep."},{"key":"10.1016\/j.phrs.2026.108432_bib193","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fncel.2019.00403","article-title":"Normal and pathological tau uptake mediated by M1\/M3 muscarinic receptors promotes opposite neuronal changes","volume":"13","author":"Morozova","year":"2019","journal-title":"Front. Cell. Neurosci."},{"issue":"7803","key":"10.1016\/j.phrs.2026.108432_bib194","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","article-title":"LRP1 is a master regulator of tau uptake and spread","volume":"580","author":"Rauch","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108432_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100715","article-title":"Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism","volume":"296","author":"Cooper","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2026.108432_bib196","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrm2216","article-title":"Pathways of clathrin-independent endocytosis","volume":"8","author":"Mayor","year":"2007","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"33","key":"10.1016\/j.phrs.2026.108432_bib197","doi-asserted-by":"crossref","first-page":"E3138","DOI":"10.1073\/pnas.1301440110","article-title":"Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds","volume":"110","author":"Holmes","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"24","key":"10.1016\/j.phrs.2026.108432_bib198","doi-asserted-by":"crossref","first-page":"14893","DOI":"10.1074\/jbc.M115.652693","article-title":"Tau trimers are the minimal propagation unit spontaneously internalized to seed intracellular aggregation","volume":"290","author":"Mirbaha","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib199","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00401-017-1722-x","article-title":"Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins","volume":"134","author":"Flavin","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.phrs.2026.108432_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102306","article-title":"Microglia: friend and foe in tauopathy","volume":"216","author":"Odfalk","year":"2022","journal-title":"Progress. Neurobiol."},{"key":"10.1016\/j.phrs.2026.108432_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.572850","article-title":"Astrocytes in tauopathies","volume":"11","author":"Reid","year":"2020","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib202","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1038\/s41598-019-41105-4","article-title":"Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fc\u03b3-receptor binding and functional lysosomes","volume":"9","author":"Andersson","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib203","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12974-018-1309-z","article-title":"The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease","volume":"15","author":"Hopp","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2026.108432_bib204","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12974-014-0161-z","article-title":"Microglia display modest phagocytic capacity for extracellular tau oligomers","volume":"11","author":"Majerova","year":"2014","journal-title":"J. Neuroinflamm."},{"issue":"49","key":"10.1016\/j.phrs.2026.108432_bib205","doi-asserted-by":"crossref","first-page":"11835","DOI":"10.1523\/JNEUROSCI.0983-17.2017","article-title":"Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes","volume":"37","author":"Rostami","year":"2017","journal-title":"J. Neurosci."},{"issue":"18","key":"10.1016\/j.phrs.2026.108432_bib206","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.neuron.2024.07.027","article-title":"Protective lifelines: tunneling nanotubes connect neurons and microglia","volume":"112","author":"Neher","year":"2024","journal-title":"Neuron"},{"issue":"18","key":"10.1016\/j.phrs.2026.108432_bib207","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1016\/j.neuron.2024.06.029","article-title":"Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes","volume":"112","author":"Scheiblich","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2026.108432_bib208","doi-asserted-by":"crossref","DOI":"10.1038\/s41593-026-02317-w","article-title":"Microglial mitochondria transfer to astrocytes via GPNMB-enriched extracellular vesicles alleviates cognitive deficits in tauopathy mice","author":"Liang","year":"2026","journal-title":"Nat. Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib209","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00401-016-1630-5","article-title":"Soluble phospho-tau from Alzheimer's disease hippocampus drives microglial degeneration","volume":"132","author":"Sanchez-Mejias","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib210","doi-asserted-by":"crossref","first-page":"9477","DOI":"10.1038\/s41598-019-45676-0","article-title":"BIN1 favors the spreading of Tau via extracellular vesicles","volume":"9","author":"Crotti","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib211","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13024-021-00440-9","article-title":"Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model","volume":"16","author":"Clayton","year":"2021","journal-title":"Mol. Neurodegener."},{"issue":"8","key":"10.1016\/j.phrs.2026.108432_bib212","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1096\/fj.08-123877","article-title":"Accumulation of tau induced in neurites by microglial proinflammatory mediators","volume":"23","author":"Gorlovoy","year":"2009","journal-title":"Faseb J."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib213","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1038\/s41467-021-26851-2","article-title":"Tau activates microglia via the PQBP1-cGAS-STING pathway to promote brain inflammation","volume":"12","author":"Jin","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib214","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41467-022-29552-6","article-title":"Microglial NF-\u03baB drives tau spreading and toxicity in a mouse model of tauopathy","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.phrs.2026.108432_bib215","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102066","article-title":"Dendrimer-conjugated nSMase2 inhibitor reduces tau propagation in mice","volume":"14","author":"Tallon","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib216","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40035-023-00383-9","article-title":"Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model","volume":"12","author":"Tallon","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.phrs.2026.108432_bib217","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jbior.2014.10.002","article-title":"Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes","volume":"57","author":"Shamseddine","year":"2015","journal-title":"Adv. Biol. Regul."},{"issue":"5","key":"10.1016\/j.phrs.2026.108432_bib218","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124481","article-title":"Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties","volume":"10","author":"Figuera-Losada","year":"2015","journal-title":"PLoS. One"},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib219","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.bbrc.2018.03.209","article-title":"Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2","volume":"499","author":"Bilousova","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib220","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2019.1703244","article-title":"Inhibiting extracellular vesicles formation and release: a review of EV inhibitors","volume":"9","author":"Catalano","year":"2020","journal-title":"J. Extracell. Vesicles"},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib221","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10110858","article-title":"Pharmacological modulators of tau aggregation and spreading","volume":"10","author":"Dominguez-Meijide","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.phrs.2026.108432_bib222","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-4598-12-4","article-title":"Inhibition of clathrin by pitstop 2 activates the spindle assembly checkpoint and induces cell death in dividing HeLa cancer cells","volume":"12","author":"Smith","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2026.108432_bib223","doi-asserted-by":"crossref","first-page":"9994","DOI":"10.1038\/srep09994","article-title":"Clathrin inhibitor Pitstop-2 disrupts the nuclear pore complex permeability barrier","volume":"5","author":"Liashkovich","year":"2015","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.phrs.2026.108432_bib224","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.208926","article-title":"Loss of PTEN promotes formation of signaling-capable clathrin-coated pits","volume":"131","author":"Rosselli-Murai","year":"2018","journal-title":"J. Cell. Sci."},{"issue":"9","key":"10.1016\/j.phrs.2026.108432_bib225","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.201908189","article-title":"Wbox2: A clathrin terminal domain-derived peptide inhibitor of clathrin-mediated endocytosis","volume":"219","author":"Chen","year":"2020","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.phrs.2026.108432_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108265","article-title":"Ext1-targeted gene therapy ameliorates tauopathy by inhibiting heparan sulfate-dependent tau propagation","volume":"230","author":"Huang","year":"2026","journal-title":"Pharmacol. Res."},{"issue":"72","key":"10.1016\/j.phrs.2026.108432_bib227","doi-asserted-by":"crossref","first-page":"10120","DOI":"10.1039\/C8CC05072D","article-title":"Binding and neurotoxicity mitigation of toxic tau oligomers by synthetic heparin like oligosaccharides","volume":"54","author":"Wang","year":"2018","journal-title":"Chem. Commun. (Camb.)"},{"issue":"49","key":"10.1016\/j.phrs.2026.108432_bib228","doi-asserted-by":"crossref","first-page":"16180","DOI":"10.1523\/JNEUROSCI.3020-14.2014","article-title":"Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury","volume":"34","author":"Iliff","year":"2014","journal-title":"J. Neurosci."},{"issue":"37","key":"10.1016\/j.phrs.2026.108432_bib229","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.1523\/JNEUROSCI.0619-21.2021","article-title":"The glymphatic system: a novel component of fundamental neurobiology","volume":"41","author":"Hablitz","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2026.108432_bib230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.neurobiolaging.2021.09.013","article-title":"Tau in the brain interstitial fluid is fragmented and seeding-competent","volume":"109","author":"Barini","year":"2022","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib231","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-024-01439-2","article-title":"Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model","volume":"16","author":"Lopes","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.phrs.2026.108432_bib232","unstructured":"N.I.o.A. (NIA), 2005. Study of Melatonin: Sleep Problems in Alzheimer's Disease, https:\/\/clinicaltrials.gov\/study\/NCT00000171?viewType=Card&intr=Melatonin&term=Tauopathies&rank=2 (accessed 21 June 2026)."},{"key":"10.1016\/j.phrs.2026.108432_bib233","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3389\/fendo.2019.00480","article-title":"Melatonin: clinical perspectives in neurodegeneration","volume":"10","author":"Cardinali","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.phrs.2026.108432_bib234","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fneur.2019.01143","article-title":"Exercise-induced neuroprotection and recovery of motor function in animal models of Parkinson's disease","volume":"10","author":"Palasz","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.phrs.2026.108432_bib235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fmolb.2019.00016","article-title":"Novel mannitol-based small molecules for inhibiting aggregation of \u03b1-synuclein amyloids in Parkinson's disease","volume":"6","author":"Paul","year":"2019","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib236","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s40478-018-0650-x","article-title":"Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas","volume":"6","author":"den Haan","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib237","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s40478-024-01907-8","article-title":"pTau pathology in the retina of TAU58 mice: association with ganglion cell degeneration and implications on seeding and propagation of pTau from human brain lysates","volume":"12","author":"Walkiewicz","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"issue":"9","key":"10.1016\/j.phrs.2026.108432_bib238","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.molmed.2022.06.004","article-title":"Particulate matter and Alzheimer's disease: an intimate connection","volume":"28","author":"O'Piela","year":"2022","journal-title":"Trends Mol. Med."},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib239","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.neuron.2022.12.029","article-title":"Virus exposure and neurodegenerative disease risk across national biobanks","volume":"111","author":"Levine","year":"2023","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib240","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-024-48462-3","article-title":"Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging","volume":"15","author":"Diez","year":"2024","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.phrs.2026.108432_bib241","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.176703","article-title":"PM2.5 triggers tau aggregation in a mouse model of tauopathy","volume":"9","author":"Liu","year":"2024","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib242","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00401-025-02902-6","article-title":"The olfactory epithelium: a critical gateway for pathological tau propagation and a target for mitigating tauopathy in the central nervous system","volume":"149","author":"Dourte","year":"2025","journal-title":"Acta Neuropathol."},{"issue":"17","key":"10.1016\/j.phrs.2026.108432_bib243","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106320","article-title":"Gut inflammation triggers C\/EBP\u03b2\/\u03b4-secretase-dependent gut-to-brain propagation of A\u03b2 and Tau fibrils in Alzheimer's disease","volume":"40","author":"Chen","year":"2021","journal-title":"Embo J."},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib244","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/gutjnl-2024-334571","article-title":"Pathological tau propagation from the brain to the colon via the vagal efferent pathway in Alzheimer's disease","volume":"75","author":"Choi","year":"2026","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib245","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020297","article-title":"Nasal rifampicin halts the progression of tauopathy by inhibiting tau oligomer propagation in alzheimer brain extract-injected mice","volume":"10","author":"Umeda","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2026.108432_bib246","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102270","article-title":"Amyloid \u03b2, Tau, and \u03b1-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases","volume":"214","author":"Sengupta","year":"2022","journal-title":"Prog. Neurobiol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108432_bib247","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.tins.2025.10.006","article-title":"Rethinking neurodegeneration through a co-proteinopathy lens","volume":"48","author":"Zhang","year":"2025","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib248","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00401-015-1525-x","article-title":"Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo","volume":"131","author":"Vasconcelos","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib249","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.2353\/ajpath.2007.070403","article-title":"Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice","volume":"171","author":"Bolmont","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"5534","key":"10.1016\/j.phrs.2026.108432_bib250","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1126\/science.1062097","article-title":"Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils","volume":"293","author":"G\u00f6tz","year":"2001","journal-title":"Science"},{"issue":"34","key":"10.1016\/j.phrs.2026.108432_bib251","doi-asserted-by":"crossref","first-page":"8985","DOI":"10.1002\/anie.201400735","article-title":"Maintenance of amyloid \u03b2 peptide homeostasis by artificial chaperones based on mixed-shell polymeric micelles","volume":"53","author":"Huang","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"9","key":"10.1016\/j.phrs.2026.108432_bib252","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2022.140817","article-title":"Development of \u03b2-sheet structure in A\u03b2 aggregation intermediates diminishes exposed hydrophobic surface area and enhances proinflammatory activity","volume":"1870","author":"Dhami","year":"2022","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib253","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s12539-018-0307-2","article-title":"An in-silico investigation of key lysine residues and their selection for clearing off A\u03b2 and Holo-A\u03b2PP through ubiquitination","volume":"11","author":"Kumar","year":"2019","journal-title":"Interdiscip. Sci."},{"key":"10.1016\/j.phrs.2026.108432_bib254","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127414","article-title":"Dual Abeta\/tau epitope vaccines: a poorly explored strategy for Alzheimer's disease immunotherapy","volume":"61","author":"Leon-Arcia","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib255","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41541-024-00942-9","article-title":"A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer's disease in 3xTg mice","volume":"9","author":"Feng","year":"2024","journal-title":"NPJ Vaccin."},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib256","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/00005072-198811000-00008","article-title":"Lewy bodies contain epitopes both shared and distinct from Alzheimer neurofibrillary tangles","volume":"47","author":"Galloway","year":"1988","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib257","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/brain\/awx255","article-title":"Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease","volume":"140","author":"Cisbani","year":"2017","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.phrs.2026.108432_bib258","first-page":"1234","article-title":"Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies","volume":"90","author":"Smith","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib259","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1469-1809.2009.00560.x","article-title":"Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease","volume":"74","author":"Edwards","year":"2010","journal-title":"Ann. Hum. Genet."},{"issue":"9","key":"10.1016\/j.phrs.2026.108432_bib260","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.phrs.2026.108432_bib261","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ng.485","article-title":"Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease","volume":"41","author":"Satake","year":"2009","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.phrs.2026.108432_bib262","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson's disease","volume":"41","author":"Sim\u00f3n-S\u00e1nchez","year":"2009","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.phrs.2026.108432_bib263","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.parkreldis.2014.12.027","article-title":"CSF tau and tau\/A\u03b242 predict cognitive decline in Parkinson's disease","volume":"21","author":"Liu","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib264","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","article-title":"Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study","volume":"16","author":"Schrag","year":"2017","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib265","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/brain\/awx118","article-title":"Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression","volume":"140","author":"Fereshtehnejad","year":"2017","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.phrs.2026.108432_bib266","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1093\/brain\/awac171","article-title":"Tau accelerates \u03b1-synuclein aggregation and spreading in Parkinson's disease","volume":"145","author":"Pan","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.phrs.2026.108432_bib267","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbrc.2021.03.091","article-title":"Tau induces formation of \u03b1-synuclein filaments with distinct molecular conformations","volume":"554","author":"Hojjatian","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib268","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40035-025-00490-9","article-title":"Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials","volume":"14","author":"Zhan","year":"2025","journal-title":"Transl. Neurodegener."},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib269","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-201334","article-title":"Bispecific tau antibodies with additional binding to C1q or alpha-synuclein","volume":"80","author":"Quint","year":"2021","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib270","article-title":"Spermine modulation of Alzheimer's Tau and Parkinson's \u03b1-synuclein: implications for biomolecular condensation and neurodegeneration","volume":"16","author":"Sun","year":"2025","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.phrs.2026.108432_bib271","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1038\/s41380-025-03277-6","article-title":"A novel lncRNA FAM151B-DT regulates degradation of aggregation prone proteins","volume":"30","author":"Renganathan","year":"2025","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib272","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1038\/s41467-022-32797-w","article-title":"The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils","volume":"13","author":"Antonschmidt","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib273","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1038\/s41467-025-64443-6","article-title":"Anle138b binds predominantly to the central cavity in lipidic A\u03b2\u2084\u2080 fibrils and modulates fibril formation","volume":"16","author":"Han","year":"2025","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2026.108432_bib274","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00401-015-1483-3","article-title":"Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies","volume":"130","author":"Wagner","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.phrs.2026.108432_bib275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104021","article-title":"Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: a randomised, double-blind, placebo-controlled phase 1a trial","volume":"80","author":"Levin","year":"2022","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib276","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/brain\/awz099","article-title":"Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report","volume":"142","author":"Nelson","year":"2019","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib277","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s11357-021-00407-0","article-title":"Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer's disease","volume":"43","author":"Latimer","year":"2021","journal-title":"Geroscience"},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib278","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41374-019-0196-y","article-title":"Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy","volume":"99","author":"Chornenkyy","year":"2019","journal-title":"Lab. Invest."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib279","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13024-023-00653-0","article-title":"TDP-43 pathology is associated with increased tau burdens and seeding","volume":"18","author":"Tom\u00e9","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib280","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00401-014-1269-z","article-title":"TDP-43 is a key player in the clinical features associated with Alzheimer's disease","volume":"127","author":"Josephs","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib281","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40478-022-01432-6","article-title":"LATE-NC aggravates GVD-mediated necroptosis in Alzheimer's disease","volume":"10","author":"Koper","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib282","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/bpa.12505","article-title":"Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi","volume":"28","author":"Smith","year":"2018","journal-title":"Brain Pathol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108432_bib283","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-021-02295-2","article-title":"TDP-43 interacts with pathological \u03c4 protein in Alzheimer's disease","volume":"141","author":"Tom\u00e9","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.phrs.2026.108432_bib284","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.brainres.2007.09.048","article-title":"Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies","volume":"1184","author":"Higashi","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2026.108432_bib285","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.nbd.2017.04.012","article-title":"TDP-43 expression influences amyloid\u03b2 plaque deposition and tau aggregation","volume":"103","author":"Davis","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"25","key":"10.1016\/j.phrs.2026.108432_bib286","doi-asserted-by":"crossref","first-page":"10600","DOI":"10.1074\/jbc.M117.783498","article-title":"Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies","volume":"292","author":"Gu","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib287","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13024-018-0237-9","article-title":"Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration","volume":"13","author":"Taylor","year":"2018","journal-title":"Mol. Neurodegener."},{"issue":"2","key":"10.1016\/j.phrs.2026.108432_bib288","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41593-017-0047-3","article-title":"TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS\/FTD","volume":"21","author":"Chou","year":"2018","journal-title":"Nat. Neurosci."},{"issue":"5","key":"10.1016\/j.phrs.2026.108432_bib289","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.neuron.2018.07.039","article-title":"Tau protein disrupts nucleocytoplasmic transport in Alzheimer's disease","volume":"99","author":"Eftekharzadeh","year":"2018","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib290","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049323","article-title":"TDP-43 promotes tau accumulation and selective neurotoxicity in bigenic Caenorhabditis elegans","volume":"15","author":"Latimer","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.phrs.2026.108432_bib291","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105130","article-title":"TDP-43 and tau oligomers in Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia","volume":"146","author":"Montalbano","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib292","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13195-025-01775-x","article-title":"Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials","volume":"17","author":"Harris","year":"2025","journal-title":"Alzheimers Res. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2026.108432_bib293","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41380-019-0563-5","article-title":"Discovery of autism\/intellectual disability somatic mutations in Alzheimer's brains: mutated ADNP cytoskeletal impairments and repair as a case study","volume":"26","author":"Ivashko-Pachima","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2026.108432_bib294","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213666","article-title":"NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies","volume":"14","author":"Ivashko-Pachima","year":"2019","journal-title":"PLoS. One"},{"issue":"5-6","key":"10.1016\/j.phrs.2026.108432_bib295","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000348347","article-title":"A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment","volume":"35","author":"Morimoto","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"7","key":"10.1016\/j.phrs.2026.108432_bib296","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108432_bib297","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1158\/1535-7163.MCT-12-0061","article-title":"TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells","volume":"11","author":"Fitzgerald","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.phrs.2026.108432_bib298","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005917","article-title":"Stabilization of microtubule-unbound tau via tau phosphorylation at Ser262\/356 by Par-1\/MARK contributes to augmentation of AD-related phosphorylation and A\u03b242-induced tau toxicity","volume":"12","author":"Ando","year":"2016","journal-title":"PLoS. Genet."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib299","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s11033-025-10938-w","article-title":"Emerging targets and translational challenges in treating paclitaxel-induced peripheral neuropathy","volume":"52","author":"Krishna","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.phrs.2026.108432_bib300","unstructured":"S.F. University of California, 2020. A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease, https:\/\/clinicaltrials.gov\/study\/NCT01966666 (accessed 21 June 2026)."},{"key":"10.1016\/j.phrs.2026.108432_bib301","unstructured":"S.F. University of California, 2020. Safety Study of TPI-287 to Treat CBS and PSP (TPI-287-4RT), https:\/\/clinicaltrials.gov\/study\/NCT02133846 (accessed 21 June 2026)."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib302","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/s41598-020-57718-z","article-title":"Epothilone D alters normal growth, viability and microtubule dependent intracellular functions of cortical neurons in vitro","volume":"10","author":"Clark","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2026.108432_bib303","unstructured":"Bristol-Myers Squibb, 2014. Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease, https:\/\/clinicaltrials.gov\/study\/NCT01492374 (accessed 21 June 2026)."},{"key":"10.1016\/j.phrs.2026.108432_bib304","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nbd.2017.02.010","article-title":"Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice","volume":"102","author":"MacPherson","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2026.108432_bib305","unstructured":"I.Inmune Bio, 2026. A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation (MINDFuL), https:\/\/clinicaltrials.gov\/study\/NCT05522387?viewType=Card&intr=XPro1595&term=Tauopathies&rank=1 (accessed 21 June 2026)."},{"issue":"4","key":"10.1016\/j.phrs.2026.108432_bib306","first-page":"273","article-title":"Neflamapimod: clinical phase 2b-ready oral small molecule inhibitor of p38\u03b1 to reverse synaptic dysfunction in early Alzheimer's disease","volume":"4","author":"Alam","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2026.108432_bib307","unstructured":"PharmatrophiX Inc, 2020. Study of LM11A-31-BHS in Mild-moderate AD Patients, https:\/\/clinicaltrials.gov\/study\/NCT03069014 (accessed 21 June 2026)."},{"issue":"6","key":"10.1016\/j.phrs.2026.108432_bib308","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/s41591-024-02977-w","article-title":"p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial","volume":"30","author":"Shanks","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108432_bib309","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10571-025-01634-1","article-title":"Tau-mitochondria interactions in neurodegeneration: mechanisms and therapeutic potential","volume":"46","author":"Castillo-Casa\u00f1a","year":"2025","journal-title":"Cell. Mol. Neurobiol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826003476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:54:16Z","timestamp":1789901656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826003476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":309,"alternative-id":["S1043661826003476"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108432","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of tauopathies: From druggable biology to precision intervention","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108432"}}